Eosinophilic Granulomatosis With Polyangiitis (EGPA)
7
3
3
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
43%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases
Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment
Vasculitis Pregnancy Registry
Clinical Transcriptomics in Systemic Vasculitis (CUTIS)
Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis
Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Eosinophil Subpopulations in Eosinophilic-associated Diseases